Cargando…

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure

BACKGROUND: Sacubitril/valsartan (S/V) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Data about the immediate, short-, and intermediate-term hemodynamic effects of S/V are limited. METHODS: In this prospective observational study, 37 outpatients with chroni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fröhlich, Hanna, Frey, Norbert, Estler, Bent, Mäck, Mirjam, Schlegel, Philipp, Beckendorf, Jan, Frankenstein, Lutz, Täger, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493168/ https://www.ncbi.nlm.nih.gov/pubmed/36136241 http://dx.doi.org/10.1007/s40256-022-00549-2

Ejemplares similares

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
por: Fabiani, Iacopo, et al.
Publicado: (2023)

Prognostic value of changes in high-sensitivity cardiac troponin T beyond biological variation in stable outpatients with cardiovascular disease: a validation study
por: Biener, Moritz, et al.
Publicado: (2021)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan
por: Dini, Frank L., et al.
Publicado: (2022)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
por: Maggioni, Aldo P., et al.
Publicado: (2022)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
por: Peppin, Katie L., et al.
Publicado: (2020)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
por: Landolfo, Matteo, et al.
Publicado: (2020)

Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis
por: Täger, Tobias, et al.
Publicado: (2021)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
por: Ding, Ying, et al.
Publicado: (2023)

N‐terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure
por: Schnorbach, Johannes, et al.
Publicado: (2019)

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
por: Rizzo, M, et al.
Publicado: (2020)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
por: López‐Azor, Juan Carlos, et al.
Publicado: (2019)

Devastating Worsening Renal Function Following the Initiation of Sacubitril/Valsartan: Falling Between Two Stools
por: Sairaku, Akinori, et al.
Publicado: (2023)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Valsartan/Sacubitril in heart failure and hypotension: how, when and why
por: Scardovi, Angela Beatrice, et al.
Publicado: (2019)

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
por: Bocchi, Edimar Alcides, et al.
Publicado: (2018)

A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan
por: Rawla, Prashanth, et al.
Publicado: (2019)

Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
por: Valentim Gonçalves, António, et al.
Publicado: (2019)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
por: Aykan, Duygun Altintas, et al.
Publicado: (2020)

Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan
por: De Vecchis, Renato, et al.
Publicado: (2020)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
por: Heyse, Alex, et al.
Publicado: (2019)

Switching to sacubitril/valsartan or adding aldosterone antagonist: which first?
por: Escobar, Carlos, et al.
Publicado: (2019)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
por: Carballo, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cbujc56bdr81894ing9hnpl47o